Madiha has been working on vector engineering and vaccine design for over 15 years. She has a strong background in applied molecular and cellular biotechnology, in virology and in immunology, with research interests at the interface of fundamental and translational research, the so-called bench-to-bedside. She especially focuses on immune stimulation and immune modulation, both in the oncology and infectious disease fields.
Madiha holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.
Madiha is also the Scientific Founder of AMAL Therapeutics, a Swiss biotech company developing first-in-class therapeutic cancer vaccines. She designed and characterized a CPP-based multi-epitopic cancer vaccine in the Laboratory of Tumour Immunology of the University of Geneva, which is the basis of the KISIMA proprietary vaccine platform. Madiha excitingly drove the integration of AMAL Therapeutics into the Boehringer Ingelheim oncology research and development family, with the acquisition of AMAL by Boehringer Ingelheim in July 2019.